PMID- 34526963
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210917
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 12
DP  - 2021
TI  - Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients 
      With Focal-Onset Seizures: An Observational, Prospective Study.
PG  - 731566
LID - 10.3389/fneur.2021.731566 [doi]
LID - 731566
AB  - Purpose: To evaluate the efficacy and tolerability of adjunctive perampanel (PER) 
      in Chinese patients with focal-onset seizures, with or without secondarily 
      generalized tonic-clonic seizures. Methods: Fifty-six patients aged 14-72 years 
      were recruited consecutively in this single-center prospective observational 
      study. All patients received PER as add-on treatment on the basis of clinical 
      judgment. Seizure frequency, adverse events (AEs), and retention rates were 
      obtained at 3 and 6 months after PER introduction. Results: The overall response 
      rates were 60 and 71.1% after 3 and 6 months, respectively, and the freedom of 
      seizures at the same points were reached in 8 and 15.8%. The retention rates were 
      89.3% at the 3-month follow-up and 67.9% at the 6-month follow-up. The overall 
      incidence of adverse events was 55.4%. The leading reported AEs were dizziness 
      (39.3%) and somnolence (25%). Conclusions: Our study confirmed the efficacy and 
      tolerability of adjunctive PER in Chinese patients in real-life conditions. Based 
      on our treatment experience, a lower maintenance dose of PER would be needed in 
      Chinese patients.
CI  - Copyright (c) 2021 Zhang, Qiao, Fang, Wang, Shi, Du, Yang and Liu.
FAU - Zhang, Ranran
AU  - Zhang R
AD  - Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong 
      University, Jinan, China.
FAU - Qiao, Shan
AU  - Qiao S
AD  - Department of Neurology, The First Affiliated Hospital of Shandong First Medical 
      University, Jinan, China.
FAU - Fang, Xiqin
AU  - Fang X
AD  - Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong 
      University, Jinan, China.
FAU - Wang, Kemo
AU  - Wang K
AD  - Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong 
      University, Jinan, China.
FAU - Shi, Yanting
AU  - Shi Y
AD  - Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong 
      University, Jinan, China.
FAU - Du, Qianwen
AU  - Du Q
AD  - Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong 
      University, Jinan, China.
FAU - Yang, Tingting
AU  - Yang T
AD  - Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong 
      University, Jinan, China.
FAU - Liu, Xuewu
AU  - Liu X
AD  - Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong 
      University, Jinan, China.
AD  - Institute of Epilepsy, Shandong University, Jinan, China.
LA  - eng
PT  - Journal Article
DEP - 20210830
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC8435584
OTO - NOTNLM
OT  - anti-seizure medication
OT  - epilepsy
OT  - focal seizures
OT  - perampanel
OT  - seizure freedom
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/17 06:00
MHDA- 2021/09/17 06:01
PMCR- 2021/08/30
CRDT- 2021/09/16 07:05
PHST- 2021/06/27 00:00 [received]
PHST- 2021/07/19 00:00 [accepted]
PHST- 2021/09/16 07:05 [entrez]
PHST- 2021/09/17 06:00 [pubmed]
PHST- 2021/09/17 06:01 [medline]
PHST- 2021/08/30 00:00 [pmc-release]
AID - 10.3389/fneur.2021.731566 [doi]
PST - epublish
SO  - Front Neurol. 2021 Aug 30;12:731566. doi: 10.3389/fneur.2021.731566. eCollection 
      2021.